MedPath

Personalized Medicine for Diabetes Prediction and Prevention of Complications

Phase 1
Conditions
Metabolic Syndrome
Diabetes
Registration Number
NCT01268813
Lead Sponsor
Rambam Health Care Campus
Brief Summary

The metabolic syndrome is a collection of related risk factors that predispose to the development of type 2 diabetes Mellitus and cardiovascular disease. The investigators will examine the hypothesis that the metabolic and genomic characteristics of patients with metabolic syndrome and/or diabetes that are at risk for developing complications differ from each other and can be detected using specific biomarkers in blood or in the exhaled breath. Early detection of these individuals will enable personalized treatment to prevent and treat diabetes and its complications

Detailed Description

Breath samples will be collected in inert respiratory bag from diabetic and healthy volunteers, and analyzed using a chamber containing nano-chemical sensors. These samples together with blood samples will additionally be characterized using Gas Chromatography-Mass Spectroscopy "GC-MS".

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Metabolic Syndrome
  • Type 2 diabetes
  • Healthy volunteers with 20<Body Mass Index<25
Exclusion Criteria
  • Smoking
  • Chronic or acute lung disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Development of Diabetes or complication2 years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Rambam Medical Center - Inst. Endocrinology, Diabetes & Metabolism

🇮🇱

Haifa, Israel

Rambam Medical Center - Inst. Endocrinology, Diabetes & Metabolism
🇮🇱Haifa, Israel
Eddy Karnieli, MD
Principal Investigator
Sagit Zolotov, MD
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.